Concerns about potential adverse effects of testosterone on prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel non steroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.